Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947995 | 0.90 | NPC1 (0.40) | CHRNA7NPC1POLBRAB9ASLC2A1 | |
| SCHEMBL11948021 | 0.85 | NCF1 (0.40) | NPC1POLBRAB9ASLC2A1NCF1 | |
| SCHEMBL11948013 | 0.85 | ALDH1A1 (0.40) | NPC1POLBRAB9ASLC2A1NCF1 | |
| SCHEMBL3066891 | 0.81 | ALDH1A1 (0.35) | SLC2A1NCF1AURKAMETKDR | |
| SCHEMBL3075437 | 0.80 | AURKA (0.40) | POLBSLC2A1NCF1AURKAMET | |
| SCHEMBL11948017 | 0.80 | SLC2A1 (0.38) | SLC2A1NCF1KDM4EALDH1A1MAPT | |
| SCHEMBL11947990 | 0.80 | KCNH2 (0.38) | SLC2A1NCF1MAOAMAOB | |
| SCHEMBL11947994 | 0.80 | SLC2A1 (0.47) | SLC2A1NCF1 | |
| SCHEMBL3063850 | 0.80 | NCF1 (0.41) | NCF1KDM4EMAPK1MTNR1AMTNR1B | |
| SCHEMBL11948041 | 0.79 | KCNH2 (0.38) | SLC2A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8242275-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8232391-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232391-B2 | Bicyclic pyrazole compounds as antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-31 | — | — | US | disclosed |
| US-7842810-B2 | 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-30 | — | — | US | disclosed |
| US-7842810-B2 | 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-30 | — | — | US | disclosed |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-11-04 | — | — | US | disclosed |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-11-04 | — | — | US | disclosed |
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | ALLISON BRETT D | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274005-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | L3MBTL1 2382/4885CHRNA7 4875/4885NPC1 1528/4885 |
| US-20100274004-A1 | BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | PIR, BAK1, TMBIM6 | L3MBTL1 2560/4885CHRNA7 4819/4885NPC1 2405/4885 |
| US-20100280240-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | NOD2, BAK1, CASP3 | L3MBTL1 2382/4885CHRNA7 4875/4885NPC1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.